Date:11/3/2009

ts in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any new products and technologies of ours; obtaining regulatory approval of our current and future products and technologies, including the recently announced total hemoglobin measurement; the risk that the implementation of our international realignment will not produce the anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), which you may obtain for free on the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    Masimo Corporation

    Investor Contact:
    Mark P. de Raad
    Executive Vice President and Chief Financial Officer
    Masimo Corporation
    (949) 297-7080
    '/>"/>
SOURCE  Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 
Related medicine news :

1. The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions
2. University Medical Center Mainz Completes Installation of Masimo Noninvasive and Continuous Hemoglobin Throughout Their Operating Rooms, Intensive Care Units and Emergency Department
3. FDNY Makes Largest First Responder Purchase of Masimo Rad-57 Pulse CO-Oximeters to Improve Survival of Firefighters and Victims of Carbon Monoxide Poisoning
4. Childrens Hospital Los Angeles Completes Conversion to Masimo SET(R) Pulse Oximetry Technology
5. IRadimed Announces 510K Clearance of the New Non-Magnetic MRidium(TM) MRI IV Pump with Integrated Masimo SET(R) SpO2 Monitoring
6. Masimo and the International Association of Fire Chiefs Launch Nationwide Health & Safety Program to Reduce Firefighter Death and Injury
7. Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System
8. The International Association of Fire Fighters and Masimo Team Up on a New Global Campaign to Raise Awareness of Carbon Monoxide-Related Death and Injury Risks for Fire Fighters
9. Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009
10. Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System
11. Masimo Announces Settlement of Lawsuit